Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

So What’s Next For Hanmi?

This article was originally published in PharmAsia News

Executive Summary

Hanmi's surprising success in R&D this year has left people wondering what strategy the leading South Korean pharma firm may take next to transform into a big global player like Takeda. With an expected massive inflow of cash from a series of big licensing out deals with multinationals, it may be poised to change its R&D strategy and even engage in some M&A.



Related Companies